Attovia is developing a pipeline of biotherapeutics for immune-mediated diseases and oncology using its proprietary ATTOBODY platform, which enables the creation of bispecific and multispecific antibodies with picomolar affinity and enhanced tissue penetration. This technology addresses the lack of effective treatment options for patients by providing first-in-class mechanisms of action that improve therapeutic efficacy.
Funding
$165M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
GSFounders
Product
Problem
Many immune-mediated diseases and cancers lack effective antibody-based therapeutics, hindering treatment options for patients. Existing treatments often fail to achieve sufficient efficacy due to limitations in target engagement and tissue penetration.
Solution
Attovia is developing a pipeline of biotherapeutics for immune-mediated diseases and oncology, utilizing its proprietary ATTOBODY platform to generate first-in-class and best-in-class multispecific antibodies. The ATTOBODY platform employs spatial positioning technology to achieve biparatopic target engagement, resulting in picomolar affinity and glue-like off-rates for enhanced potency. The platform's unconstrained engineering allows for the development of multispecific biologics with tunable half-lives, potentially enabling less frequent dosing in patients. Attovia's high-throughput, evolution-based discovery platform accelerates and de-risks therapeutics development, offering the potential to become the next-generation modality of choice.
Target Audience
The primary target audience includes patients with immune-mediated diseases and cancer, as well as pharmaceutical companies seeking novel therapeutic modalities.
Features
- ATTOBODY platform enables the creation of bispecific and multispecific antibodies.
- Spatial positioning technology achieves biparatopic target engagement.
- Picomolar affinity and glue-like off-rates enhance potency.
- Unconstrained engineering allows for tunable half-life.
- High-throughput, evolution-based discovery platform accelerates development.